Egyptian International Pharmaceutical Investments (CAI:PHAR) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
70 GF Score
Price E£86.07
GF Value E£59.81
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Egyptian International Pharmaceutical Investments's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CAI:PHAR vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's Margin of Safety % (DCF Earnings Based) falls into.


CAI:PHAR
70GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£86.07 is trading 43.9% above its estimated GF Value™ of E£59.81. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: E£59.81 vs. price of E£86.07 (43.9% above fair value)
  • GF Score™: 70/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score

Get the complete analysis for CAI:PHAR

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£86.07
Price
E£59.81
GF Value